Corporate GovernanceMay 27, 2026, 04:32 PM
ICON plc Restates Financials for 2023-2025; Q3 2025 Net Income $(284.2)M
AI Summary
ICON plc announced the restatement of its audited financial statements for the years ended December 31, 2024 and 2023, and unaudited interim financial statements for quarterly periods between March 31, 2023, and September 30, 2025. This action follows an Audit Committee investigation that identified improper adjustments to clinical trial services revenue and errors in cost estimation and realizable value. The restatement also includes significant additional goodwill and non-financial asset impairments, leading to a substantial negative adjustment to net income for the affected periods.
Key Highlights
- Restated audited financial statements for years ended December 31, 2024 and 2023.
- Restated unaudited interim financial statements for quarterly periods from March 31, 2023, to September 30, 2025.
- Investigation found improper adjustments to clinical trial services revenue from Q3 2023 to Q4 2024.
- Identified errors in estimated cost to complete, realizable value, and manual adjustments for clinical trial services.
- Recorded additional goodwill impairment of $198,948 thousand at September 30, 2025.
- Recorded impairment of non-financial assets of $101,027 thousand at September 30, 2025.
- Q3 2025 net income restated to $(284,183) thousand from $2,355 thousand as reported.
- Accounts receivable overstated by $160.0 million at March 31, 2024.
Price Impact
More from ICLR